Sample size calculation in economic evaluations..作者:Al MJ; van Hout BA; Michel BC; Rutten FF.
作者地址:Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands. al@econ.bmg.eur.nl.
来源:[Health Econ] Health Economics 1998 Jun; Vol. 7 (4), pp. 327-35. .
出版物类型:Comparative Study; Journal Article; Research Support, Non-U.S. Gov't.
语言:English.
Journal Information:Publisher: Wiley : Chichester Country of Publication: ENGLAND NLM ID: 9306780 Publication Model: Print Cited Medium: Print ISSN: 1057-9230 (Print) Linking ISSN: 10579230 NLM ISO Abbreviation: Health Econ Subsets: MEDLINE.
MeSH 词语:Cost-Benefit Analysis*
Sample Size*
Health Services Research/*methods
2-Pyridinylmethylsulfinylbenzimidazoles ; Angioplasty, Balloon, Coronary/economics ; Anti-Ulcer Agents/economics ; Anti-Ulcer Agents/therapeutic use ; Costs and Cost Analysis ; Esophagitis, Peptic/drug therapy ; Esophagitis, Peptic/economics ; Fibrinolytic Agents/economics ; Fibrinolytic Agents/therapeutic use ; Humans ; Models, Statistical ; Myocardial Infarction/drug therapy ; Myocardial Infarction/economics ; Myocardial Infarction/therapy ; Omeprazole/analogs & derivatives ; Omeprazole/economics ; Omeprazole/therapeutic use ; Probability ; Streptokinase/economics ; Streptokinase/therapeutic use.
摘要:A simulation method is presented for sample size calculation in economic evaluations. As input the method requires: the expected difference and variance of costs and effects, their correlation, the significance level (alpha) and the power of the testing method and the maximum acceptable ratio of incremental effectiveness to incremental costs. The method is illustrated with data from two trials. The first compares primary coronary angioplasty with streptokinase in the treatment of acute myocardial infarction, in the second trial, lansoprazole is compared with omeprazole in the treatment of reflux oesophagitis. These case studies show how the various parameters influence the sample size. Given the large number of parameters that have to be specified in advance, the lack of knowledge about costs and their standard deviation, and the difficulty of specifying the maximum acceptable ratio of incremental effectiveness to incremental costs, the conclusion of the study is that from a technical point of view it is possible to perform a sample size calculation for an economic evaluation, but one should wonder how useful it is..
物质命名法:0 (2-Pyridinylmethylsulfinylbenzimidazoles)
0 (Anti-Ulcer Agents)
0 (Fibrinolytic Agents)
103577-45-3 (lansoprazole)
73590-58-6 (Omeprazole)
EC 3.4.- (Streptokinase).
Entry Dates:Date Created: 19981002 Date Completed: 19981002 Latest Revision: 20101118.